R. Stevens

发表

Outcome for children with relapsed acute myeloid leukaemia following initial therapy in the Medical Research Council (MRC) AML 10 trial

K. Wheatley, G. Harrison, I. Hann, 1999, Leukemia.

Impact of Marrow Transplantation in Acute Myeloid Leukemia in First Complete Remission: Experience from MRC AML-10 Trial

A. Burnett, K. Wheatley, A. Goldstone, 1997 .

Comparison of allogeneic transplant versus chemotherapy for relapsed childhood acute lymphoblastic leukaemia in the MRC UKALL Rl trial

S. Lawson, O. Eden, G. Harrison, 2005 .

Failure of allogeneic bone marrow transplantation to correct Diamond–Blackfan anaemia despite haemopoietic stem cell engraftment

O. Eden, A. Will, T. Carr, 1999, Bone Marrow Transplantation.

Allo and auto BMT reduce relapse risk in AML in CR1 but do not significantly improve overall survival Results of the MRC AML 10 trial

R. Gray, A. Burnett, K. Wheatley, 1996 .

A simple, robust and highly predictive prognostic index for the determination of risk directed therapy in acute myeloid leukaemia (AML) derived from the United Kingdom medical research council (MRC) AML10 trial.

R. Gray, A. Burnett, K. Wheatley, 1995 .

Bone marrow transplantation for thalassaemia: experience of two British centres.

A. Vellodi, S. Picton, D. Evans, 1994, Bone marrow transplantation.

Clinical features, cytogenetics and outcome in acute lymphoblastic and myeloid leukaemia of infancy: report from the MRC Childhood Leukaemia working party

H. Kempski, K. Wheatley, G. Harrison, 2002, Leukemia.